FTH1 and non-small cell lung carcinoma: In addition to nanobodies, other nanoscale compounds, such as a copper (II) agent based on human serum albumin and a rhodium (III) complex delivered via apoferritin,[37] have been shown promise in overcoming drug resistance of NSCLC.